“Although many teething technical problems and lack of quality data are currently restraining uptake, the expected shift of ongoing research efforts from the academic to the commercial arena in the near future will definitely support greater use of these tools in the drug discovery process.”
“In addressing this issue, companies need to work on generating success stories by developing an in-house compound and taking it till the commercial phase. Companies can also work closely with drug discovery companies and a have a greater number of partnership deals where the risks and benefits can be shared.”
“The life sciences industry is now in a period of transition, as it seeks to use IT in resolving the process inefficiencies that cause a lot of dollars to be wasted across the spectrum, from R&D to post-marketing. These companies are now witnessing a sharp uptake of IT tools, which is not limited to the drug discovery process in the life sciences industry.”
